Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
Open accessThe DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index; 93 of the 166 sources its claims cite were checked for support.
Abstract
Therapies based on glucagon-like peptide-1 (GLP-1) reduce rates of cardiovascular and chronic kidney disease in people with type 2 diabetes and/or obesity, with ongoing clinical trials investigating their effects in people with metabolic liver disease, arthritis, and both substance use and neurodegenerative disorders. Acute and chronic activation of GLP-1 receptor signaling also reduces systemic and tissue inflammation in mice and humans, through weight loss-dependent and -independent mechanisms, actions that may contribute to the expanding spectrum of clinical benefits ascribed to GLP-1 medicines. In this Review, we highlight current understanding of the direct and indirect antiinflammatory effects and mechanisms of GLP-1 medicines in both preclinical and clinical studies, covering emerging concepts, clinical relevance, and areas of uncertainty that require further investigation.
Overview
CoChat Summary
TL;DR
This review argues that GLP-1-based therapies have antiinflammatory effects beyond their metabolic benefits, with evidence from preclinical and clinical studies across many organ systems. It also highlights that both direct immune-cell actions and indirect neural/metabolic mechanisms likely contribute, but the relative importance of each remains uncertain.
Key findings
- GLP-1 medicines lower inflammatory biomarkers in people with T2D and/or obesity, including plasma CRP; in semaglutide SUSTAIN and PIONEER trials, glucose and weight explained only 20%–60% of the observed CRP reductions.
- In preclinical models, acute GLP-1R agonism reduces inflammation independent of major weight loss, for example exenatide or semaglutide reduced circulating TNF-α in LPS-challenged mice, and exenatide downregulated TNF and IL1B in human PBMCs.
- The review highlights organ-specific antiinflammatory signals: in osteoarthritis, semaglutide improved WOMAC score by –41.7 points versus –27.5 with placebo in STEP-9; in MASH, semaglutide resolved steatohepatitis without worsening fibrosis in 63% versus 34% with placebo, and improved fibrosis without worsening steatohepatitis in 37% versus 23%.
- Clinical kidney data also support antiinflammatory/anti-fibrotic benefit: in FLOW, once-weekly 1 mg semaglutide reduced the primary composite risk by 24% and delayed CKD progression over 4 years.
Methods
- Narrative review synthesizing preclinical and clinical evidence on GLP-1 medicines and inflammation across intestinal, cardiovascular, liver, kidney, pulmonary, arthritis, and neuroinflammatory contexts.
- Draws on mouse models, human cell experiments, knockout/lineage-tracing studies, and randomized clinical trials and post hoc analyses; no new primary dataset is reported in the text provided.
- Main analytic approach is comparative interpretation of direct versus indirect antiinflammatory mechanisms, including weight loss–dependent and weight loss–independent effects.
Limitations
- The paper states that distinguishing metabolic from non-metabolic antiinflammatory effects will require complementary transgenic models, pair-feeding experiments, and interdisciplinary techniques; this indicates that current evidence is not sufficient to isolate mechanisms.
- Several mechanistic claims are explicitly uncertain, including the role of specific GLP-1R-expressing cells in heart, lung, liver, kidney, and brain, and whether neural mechanisms explain human biomarker changes.
- Evident from the text: this is a review, so conclusions depend on the quality and heterogeneity of prior studies rather than a single controlled experiment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
78 Valid · 3 Not valid · 49 Not checked · 22 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Both mouse and human endocardial endothelial cells express Glp1r/GLP1R (57).”
§ Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits > GLP-1 medicines in cardiovascular inflammation
What the sources say
- Disputedcites [57] sourceExperimental — accuracy not yet measured
The Results report Glp1r expression in mouse endocardial endothelial cells, but say human endocardial endothelial cells did not co-localize with GLP1R expression. The Discussion describes this as a species-specific difference. The Conclusions and limitations caution that human endocardial cells were underrepresented in the datasets, limiting detection; the paper therefore does not establish their expression of GLP1R. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Administration of LPS, an endotoxin derived from Gram-negative bacteria that activates innate immunity and increases proinflammatory cytokines such as TNF-α, IL-6, and IL-1β, elevates circulating GLP-1 within 3 hours in mice and humans (5–7).”
§ Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits > GLP-1–producing L cells as pathogen and inflammation sensors
What the sources say
- Not checked — no full text of the sourcecites [5] source
- Supportedcites [6] source
Figure 2 (p. 5) reports plasma GLP-1 measurements 3 hours after LPS injection in mice, and the results (p. 4) state that LPS induced circulating GLP-1. The human results (p. 6) report increased plasma GLP-1 3 hours after LPS injection, compared with saline. (LLM, conf=0.93)
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
The Results section reports increased plasma GLP-1 in mice after LPS injection, with measurements at 3 hours (Figure 3). It also says prior evidence links LPS administration to increased GLP-1 secretion in mice and humans, but our copy does not establish the 3-hour timing in humans. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Both LPS- and IL-1β–induced GLP-1 release partly depends on IL-6 as shown in Il6–/– mice (5, 6), although the source of IL-6 that triggers L cells is unclear.”
§ Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits > GLP-1–producing L cells as pathogen and inflammation sensors
What the sources say
- Not checked — no full text of the sourcecites [5] source
- Partly supportedcites [6] sourceExperimental — accuracy not yet measured
In “LPSs Induce GLP-1 Secretion through a TLR4Dependent Pathway” (p. 4), LPS caused an attenuated but detectable increase in GLP-1 secretion in Il6-deficient mice, supporting partial IL-6 dependence for the LPS response. The passages do not establish the same result for IL-1β-induced release in Il6-deficient mice. (LLM, conf=0.88)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In humans, LPS infusion raises GLP-1 levels in healthy young subjects (9).”
§ Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits > GLP-1–producing L cells as pathogen and inflammation sensors
What the sources say
- Partly supportedcites [9] sourceExperimental — accuracy not yet measured
The Conclusion reports elevated GLP-1 after dual LPS exposure, and the Discussion identifies the participants as healthy young men. The claim omits the prolonged, dual-exposure condition: the Discussion also notes that GLP-1 decreased during the first six hours of LPS exposure in a separate study of healthy young men. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“For example, a single dose of exenatide or semaglutide reduced circulating TNF-α levels in mice challenged with LPS (21, 22).”
§ Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits > Weight loss–independent antiinflammatory effects of GLP-1 medicines
What the sources say
- Supportedcites [21] source
The Methods describe a single subcutaneous dose of semaglutide before an LPS challenge in mice. The Results report that semaglutide reduced plasma TNF-α at both 1 and 4 hours. This source supports the semaglutide part of the jointly cited sentence; it does not test exenatide. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [22] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
88 more claims · 43 with their cited sources checked
Create a free account to see all 152 claims and every source verdict.
- It may state two separate claims as one. 56
- Probably not a substantial claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“anti‐inflammatory cytokines such as IL‐4 and IL‐10, together with additional metabolic mediators and adipokines including ghrelin, may provide complementary insight into the counter‐regulatory and immunometabolic effects of incretin‐based therapies in T2DM [65]”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [65]
Experimental — accuracy not yet measured
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482 · cited 1×
“…have not been attributed to GLP-1 action in specific organs or cell types, the kidney GLP-1R has been localized primarily to vascular smooth muscle cells within renal arteries and arterioles using either 125 I-labeled exendin-4, a validated anti–GLP-1R antibody, or in situ hybridization (71, 72).”
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“In parallel, daily treat-ment with 50 μ g/kg liraglutide for 20 weeks improved urine chemistry and podocyte histology in Ins2 Akita mice, a transgenic model of spontaneous diabetes.”
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 2×
“In parallel, daily treat-ment with 50 μ g/kg liraglutide for 20 weeks improved urine chemistry and podocyte histology in Ins2 Akita mice, a transgenic model of spontaneous diabetes.”
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 1×
“Multiple GLP-1 medicines, including exenatide (15), liraglutide (16), semaglutide (17, 18), and tirzepatide (19), reduce plasma CRP levels in people living with T2D and/or obesity.”
Colchicine in Patients with Chronic Coronary Disease
Nidorf, S. M., Fiolet, A. T. L., Mosterd, A., Eikelboom, J. W., Schut, A., Opstal, T. S. J., The, S. H. K., Xu, X.-F., Ireland, M. A., Lenderink, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021372 · Cited by 2,299 · cited 1×
“…have not been attributed to GLP-1 action in specific organs or cell types, the kidney GLP-1R has been localized primarily to vascular smooth muscle cells within renal arteries and arterioles using either 125 I-labeled exendin-4, a validated anti–GLP-1R antibody, or in situ hybridization (71, 72).”
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099 · cited 1×
“…bowel disease (85), further research is needed to understand the significance of the GLP-1R downregulation during inflammatory bowel disease and how GLP-1 medicines interact with inflammatory bowel disease through both metabolic improvements and direct antiinflammatory actions on the intestine.”
Hallmarks of neurodegenerative diseases
Wilson, D. M., Cookson, M. R., Van Den Bosch, L., Zetterberg, H., Holtzman, D. M., & Dewachter, I. (2023) · Cell · doi:10.1016/j.cell.2022.12.032 · Cited by 1,789 · cited 1×
“Neuroinflammation is a hallmark of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases (45).”
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669 · cited 1×
“Whether the renal arterial GLP-1R mediates the antiinflammatory actions of GLP-1 medicines in the kidney remains to be determined.”
Cited by
GLP-1 physiology and pharmacology along the gut-brain axis
Beutler, L. R. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194744 · Cited by 35
“These are likely mediated in large part by the pleiotropic antiinflammatory effects of GLP-1RAs (147).”
Voros, C., Chatzinikolaou, F. G., Papapanagiotou, I., Polykalas, S., Mavrogianni, D., Koulakmanidis, A.-M., Athanasiou, D., Kanaka, V., Bananis, K., Athanasiou, A. I., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020759 · Cited by 34
“Activation of GLP-1R in adipocytes inhibits the activity of pro-inflammatory cytokines such as TNF-α and IL-6, while initiating lipolysis, browning, and the secretion of adiponectin [6].”
The many pathways driving liver inflammation in MASH
Tilg, H., Adolph, T. E., Romeo, S., & Loomba, R. S. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.02.018 · Cited by 20
GEORGAKOPOULOU, V. E., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100449 · Cited by 10
“Importantly, several of these effects have been observed in experimental settings that minimize or exclude weight change, supporting the existence of weight-independent pulmonary mechanisms [29].”
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review
Sheth, S., Merola, J. F., Weber, B. N., Prussick, R. B., Yeung, J., Liu, C., Glick, B. P., Reddy, S. M., Cook-Bolden, F. E., Wallace, E. B., et al. (2026) · JAMA Dermatology · doi:10.1001/jamadermatol.2026.0859 · Cited by 17
Operationalizing Chronic Inflammation: An Endotype-to-Care Framework for Precision and Equity
Ramos‐Niño, M. E. (2025) · Clinics and Practice · doi:10.3390/clinpract15120233 · Cited by 9
“Metformin, GLP-1 receptor agonists, and AMPK activators improve metabolic–immune coupling [1,4,22,41,42], and mTOR, HIF 1 α , and glycolysis inhibitors as well as targeted antioxidant strategies (mitochondria-directed ROS scavengers; Nrf2 activators) can modulate maladaptive myeloid activation [2].”
Tsakiridis, E. E., & Steinberg, G. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70624 · Cited by 9
Anti-inflammatory effects of GLP1-RA drugs
Quintana, L., Tabaza, N., Kurt, B., & Kahles, F. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag218 · Cited by 7
Kanbay, M., Shah, E., AlShiab, R., Ozbek, L., Ay, S., Rustamov, A., Covic, A., Mallamaci, F., & Zoccali, C. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.71106 · Cited by 4
Management of the kidney transplant candidate with obesity
Abbasi, A. B., & Orandi, B. J. (2026) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001266 · Cited by 3
Karacabeyli, D., & Lacaille, D. V. (2026) · Rheumatology · doi:10.1093/rheumatology/keag147 · Cited by 4
“Myeloid cells express the GLP-1 receptor less than lymphoid cells, and GLP-1 receptor expression on peripheral blood mononuclear cells is low overall [45].”
InfluentialSamuel, A. H., Kshatri, A. H. S., Babu, R. N., Patel, H. S., Viswanathan, S. H., Challa, M. S. R., & Swathi, N. L. (2026) · Annales d Endocrinologie · doi:10.1016/j.ando.2026.102494 · Cited by 4
Frey, C. (2026) · Future Oncology · doi:10.1080/14796694.2026.2654735 · Cited by 6
Wang, D., Jabile, M. J. T., Pastena, F. D., Townsend, L. K., Ahmadi, E., Hoegl, A., Payne, A., Lavoie, D. C. T., Batchuluun, B., Gautam, J., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.07.008 · Cited by 4
Hsieh, T. Y. J., Yen, T., Hacker, M. R., Dottino, J. A., & Esselen, K. M. (2026) · Gynecologic Oncology · doi:10.1016/j.ygyno.2026.03.010 · Cited by 4
Survival association of GLP-1 receptor agonists and SGLT2 inhibitors in bladder cancer patients
Kohler, J., Buck, L., Schließer, P., Weische, O., Risch, J., Voran, J. C., Jarczyk, J., Nuhn, P., & Rodler, S. (2026) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2026.05.010 · Cited by 4
Vear, A., Olsen, S. A., Lange, E. C. H., Müller, M. A., Svendsen, C., & Clemmensen, C. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102906 · Cited by 3
Repurposed Systemic Pharmacologic Agents in Chronic Pain: Emerging Mechanistic and Clinical Insights
McKenzie, A., Dombrower, R., Bittar, T. G., McKenzie, S. M., Theeraphapphong, N., Shukla, N., Hussain, H., & Abd-Elsayed, A. A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041572 · Cited by 2
“GLP-1 receptor agonists, commonly used to treat type 2 diabetes and obesity, exhibit potent anti-inflammatory and neuroprotective effects that extend beyond glycemic management [30].”
Catanese, B. P., Miller, C., Wolf, M. S., & Edmonston, D. L. (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001061 · Cited by 3
Obesity and Cancer: From Systemic Metabolic Reprogramming to Immunotherapy Paradox
Han, G., Yuan, S., & YU, W. (2026) · Metabolites · doi:10.3390/metabo16030174 · Cited by 4
Muir, K. C., Stone, C. R., Harris, D. D., Kanuparthy, M., Broadwin, M., Hamze, J., Feng, J., & Sellke, F. W. (2026) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00828.2025 · Cited by 5
Meza, A. D. V., Nocek, M. J., Mitchell, B. C., Lizarraga, M. A., DeFoor, M. T., Ruzbarsky, J. J., Huard, J., & Philippon, M. J. (2026) · JBJS Reviews · doi:10.2106/jbjs.rvw.26.00027 · Cited by 3
Metabolic Reprogramming and ILC2 Plasticity in Obesity-related Asthma
Piao, X. L., Hang, Y., Bai, L., Wu, M., Liu, X., & Yu, J. (2026) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-026-09169-z · Cited by 1
“The clinical benefits of GLP−1RAs in inflammatory diseases often precede or surpass significant weight loss [167 , 168].”
Hsu, J., Ho, B., Sayed, R., Patel, N. T. P., & Dardik, A. (2026) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2026.02.003 · Cited by 2
Dhali, A., Maity, R., Khan, F., Biswas, J., & Faisal, A. R. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-05125-5 · Cited by 2
Gómez-Martín, Á., Marqués, P., Recatalá, C. A., Vea, À., Domingo, E., Alabadí, B., Real, J. T., Sanz, M., & Piqueras, L. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108321 · Cited by 2
Huang, Y., Tsou, M.-Y., Li, P., Chen, J.-C., Chen, S.-C., Hsieh, H., Meyerowitz‐Katz, G., Liu, Y., & Su, P. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70786 · Cited by 3
“One interpretation is that the association tracks with metabolic changes observed in GLP-1RA trials; however, residual confounding and differential ascertainment (e.g., diagnostic work-up) remain plausible [26, 27].”
Huang, S.-C., Wu, J.-Y., Kuo, C.-Y., Hsu, W., Tsai, Y., & Lai, C. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s609054 · Cited by 5
Crawford, P. A., Rhein, J., Chipman, J. G., Beilman, G. J., Cromarty, R. T., Escandón-Vargas, K., Anderson, J. L., Wieking, G., Johnston, A., Ahmed, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.09.698696 · Cited by 5
Current therapeutic landscape and future treatment perspectives of MASH
Gallage, S., Govaere, O., Anstee, Q. M., Shulman, G. I., Tacke, F., & Heikenwälder, M. F. (2026) · Nature · doi:10.1038/s41586-026-10672-8 · Cited by 7
“Common side effects of GLP-1RAs include nausea, vomiting, diarrhoea, constipation and/or sarcopenia in up to 60% of patients 21 .”
InfluentialGLP-1 Receptor Agonists in Periodontology: Mechanisms, Clinical Evidence, and Implications for Care
Șufaru, I.-G., Vasiliu, B. C., Hăncianu, M., Stratul, Ş., Tatarciuc, M., Iovan, G., Tatarciuc, D., Rudnic, I., Hanu, D., Paduraru, S., et al. (2026) · Biomolecules · doi:10.3390/biom16060857 · Cited by 6
“In addition, agents differ in their anti-inflammatory profiles: recent evidence suggests that tirzepatide’s dual GIP/GLP-1R agonism may confer additional anti-inflammatory activity through direct actions on GIP receptor-expressing immune cells [37].”
Weight-loss-independent actions of GLP-1 medicines
Gonzalez-Rellan, M. J., & Drucker, D. J. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.07.006 · Cited by 3
Self-citationDivya, A., Dalal, N., Yoshida, Y., Kanwar, M. K., Catarino, P., & DʼAlessandro, D. A. (2026) · ASAIO Journal · doi:10.1097/mat.0000000000002804 · Cited by 1
Protective Impact of GLP-1 Therapy on Post-ERCP Outcomes: A TriNetX Retrospective Cohort Analysis
Kazi, M. A. I., Khan, J., Mufarrih, S. M., Widmer, J., Al-Sabban, A. M., Irani, S. S., Baron, T. H., & Canakis, A. (2026) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002374 · Cited by 1
Kidney angiopoietin-like protein 4 regulates fibrotic responses in diabetic kidney disease
Srivastava, S. P., Arora, A., Hamed, M., Urval, A., Dupati, A., Xia, S., Yoshida, S., & Inoki, K. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1803412 · Cited by 1
“Liraglutide and semaglutide are representative analogs of GLP-1 RAs that provide benefits by improving metabolic regulation, promoting weight loss, lowering blood pressure, and minimizing oxidative stress and systemic inflammation (Wong and Drucker, 2025; Abasheva et al., 2024).”
Sentis, G., Kalantzi, C., Flouda, S., et al. (2026) · Journal of Autoimmunity · doi:10.1016/j.jaut.2026.103634
Xu, W., Lu, C., Xu, J., & Wang, L. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106846
Cuggy, C., & O’Broin, E. (2026) · Aesthetic Surgery Journal Open Forum · doi:10.1093/asjof/ojag163 · Cited by 1
“7 In the context of metabolic syndrome and chronic wound-healing impairment from obesity-related inflammation, this is a favorable effect.”
Zhou, R., Yue, M., Shen, Q., Liu, N., Chen, Y., Wang, P., Kim, K., Yang, R., Chen, H., Yuen, K.-Y., et al. (2026) · Journal of Virology · doi:10.1128/jvi.00401-26
Kim, E. Y., & Feinstein, M. J. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.02.024 · Cited by 5
Extending concerns about GLP-1R antibody specificity to human immune cells
Pyburn, J. S., Zhao, J., Wang, L., Schank, M., Hill, A. C., Banik, P., Orfield, H. K., Hensley, C. R., Moorman, A. B., Wu, Y., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.08.007 · Cited by 1
Kurowski, M., Rekiel, K., Marcinkowska, A., Ratajczyk, O., Urbanowicz, P., Iwankiewicz, S., Grzelczak, W., & mierczak, Z. K. (2026) · Medical Journal of Cell Biology · doi:10.2478/acb-2026-0005
Wang, J., Pederson, A. M., Flanders, M. D., Choi, M., Buto, P. T., Sims, K. D., Chen, R., Couch, E., Gilsanz, P., Hayes, K. N., et al. (2026) · medRxiv · doi:10.64898/2026.09.04.26362304
Liposuction, lipectomy, or combined techniques for Madelung’s disease: A systematic review
Brandt, J., Karakas, E., Niederegger, T., et al. (2026) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2026.02.031
Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis
Chen, Q.-X., Xiao-yu, Z., Wu, Q., Xie, J.-J., Xu, Y., Teng, F., & Guo, M. (2026) · Endocrine · doi:10.1007/s12020-026-04757-7
“…state exacerbates health hazards through synergistic pathological mechanisms [ 6 ], including chronic low-grade inflammation that drives atherosclerotic cardiovascular disease, metabolic dysfunction–associated steatohepatitis, and chronic kidney disease in people with obesity and T2DM [ 7 ].”
Tirzepatide attenuates atherosclerosis through weight loss-independent anti-inflammatory mechanismsPreprint
Chen, S., Wei, S., Tian, T., Liu, Z. H., Su, M., Zhang, F.-S., Yin, Y., Chen, M., Jiang, L., Evans, P. C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.22.733886
Dardari, D. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261478400
“16 Candidate mechanisms include improved epithelial barrier integrity, altered mucus-layer biology, bile-acid and microbiome-mediated metabolic shifts, neuroimmune signalling, and activation of mucosal repair pathways.”
Wyles, S. P., Gopinath, S., Lynn, B., Pfizenmaier, Z., Ozarslan, B., & Purushothaman, K. (2026) · Dermatologic Surgery · doi:10.1097/dss.0000000000005186 · Cited by 2
Decoding Immunometabolic Dynamics of Adipose Tissue in Obesity: Evolving Evidence and Way Forward
Kumari, K., Verma, K., Yadav, R., Dwivedi, J., Paliwal, S., & Sharma, S. K. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00071
Jain, V., McMullen, C. A., Kimbrough, J., Rockich, A. K., Davenport, D. L., Hawk, G. S., Nikolajczyk, B. S., Kern, P. A., Fisher, S. J., Steiner, J. P., et al. (2026) · Journal of Surgical Research · doi:10.1016/j.jss.2026.01.004
“30,31 GLP-1 receptor activation reduces proinflammatory cytokine production, shifts macrophages toward a more anti-inflammatory phenotype, and attenuates NF-κ B—mediated inflammatory pathways.”
Li, Y., Hsu, J.-T., Fu, C.-M., Liu, T.-C., Lee, Y., Wu, P.-J., Li, L., Chiou, T. T., Chiu, C.-H., Kuo, W., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19101502
Schechter, M., Sehtman-Shachar, D. R., Fishkin, A., Mosenzon, O., Cukierman‐Yaffe, T., Sharon, R., Leibowitz, G., Arkadir, D., & Aharon‐Hananel, G. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70315 · Cited by 1
“43 Such anti-inflammatoryeffects,whichappeartooperateindependentlyofGLP-1 RA metabolic actions, 43 may also explain potential neurocognition benefits.”
Nukaly, H. Y., & Elston, D. M. (2026) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2026.08.086 · Cited by 1
Hernández‐Pérez, J. G., Abdelgadir, O., Albayyaa, M., Ernest, D. K., Chen, J., DeSantis, S. M., Hong, A. S., Cowell, L. G., Almandoz, J. P., Messiah, S. E., et al. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag197
Cuatrecasas, G. (2026) · Atención Primaria · doi:10.1016/j.aprim.2026.103496
Askari, A., Bazmi, S., Dehghani, M., Sepehrinia, M., & Poursalehian, M. (2026) · JBJS Reviews · doi:10.2106/jbjs.rvw.26.00049 · Cited by 1
Wang, J. E., Phillips, M., Nadarajah, V., & Lockey, S. D. (2026) · HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1177/15563316261455872 · Cited by 1
“11 The metabolic and anti-inflammatory effects may enhance physiologic resilience in the perioperative period, which is recognized as a modifiable determinant of surgical recovery in medically complex patients.”
Heart and Brain: Linking Obesity-Related Inflammation, Cardiovascular Disease and Cognitive Function
Reiss, A. B., Gulkarov, S., Syed, U., Ben-Dor, G. A., Srivastava, A., Singh, M., & Leon, J. D. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13100477
Reitz, J., Rosoff, D. B., Pacher, P., & Lohoff, F. W. (2026) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2026.100793 · Cited by 1
“GLP-1 therapies also influence gut bacterial load and regulate inflammation across the brain, liver, and gut (31,32)—both key pathological components of met-ALD.”
GLP-1 receptor agonists, epigenetic aging, and the prospect of pharmacological healthspan extension
Al‐Ali, D., & Hajj, N. E. (2026) · Experimental Gerontology · doi:10.1016/j.exger.2026.113325
Losing Muscle or Restoring Physiology? Reframing the Incretin Therapy Sarcopenia Concern
Koufakis, T., Tentolouris, A., Karakasis, P., Popovic, D. S., & Patoulias, D. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03804-z
Glucagon-like peptide-1 receptor agonists as metabolic adjuncts in immune-mediated skin disease
Lazarowitz, R., Saroufim, L., Sauder, M. B., Osman, M. S., Tardio, V., Litvinov, I. V., & Netchiporouk, E. (2026) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2026.02.047
Tong, L. H., Leung, K.-K., & Hung, C.-T. (2026) · Journal of Chromatography A · doi:10.1016/j.chroma.2026.467288
Are GLP-1 receptor agonists gerotherapeutics or just treatments for obesity?
Peyer, J. G. (2026) · Nature Aging · doi:10.1038/s43587-026-01165-4
Immunometabolism and rheumatic disease—advancing targeted therapies
Boothby, M. R. (2026) · EULAR Rheumatology Open · doi:10.1016/j.ero.2026.100235
Islam, B. N., Nguyen-Gomez, A., Williams, K., Curry, K., Khandekar, N. S., Chieppa, M., Xin, W., Pizarro, T. T., Wang, R., & Cominelli, F. (2026) · Gut · doi:10.1136/gutjnl-2025-337537 · Cited by 1
“6 Recent evidence suggests that GLP-1 receptor agonists may also possess anti-inflammatory properties, including reducing colitis severity in mouse models of intestinal injury.”
GLP-1 Receptor Agonists beyond Glycemic Control: Physiology and Pharmacological Evidence
Amate, P. (2026) · Open Journal of Pharmacology and Pharmacotherapeutics · doi:10.17352/ojpp.000029
Bowers, C. J., Ruelos, V. C. B., Roy, J. C., & Weiss, W. M. (2026) · Journal of orthopaedic surgery · doi:10.1177/10225536261488188
GLP-1 Receptor Agonist Use in Cancer Survivors—Challenges and Opportunities: A Narrative Review
Agurs‐Collins, T., & Sauter, E. R. (2026) · Cancers · doi:10.3390/cancers18162714
“There is evidence that GLP-1 receptor signaling has intrinsic anti-inflammatory actions that are not dependent on weight loss [22].”
Semaglutide and Its Potential Hepatoprotective Effects Against Acute Drug-Induced Liver Injury
Charatsi, E., Liberopoulos, E. N., Pergialiotis, V., Kontzoglou, K., Kykalos, S., & Iliopoulos, D. (2026) · Cureus · doi:10.7759/cureus.107715
“GLP-1-based therapies have been shown to reduce circulating levels of pro-inflammatory cytokines and modulate immune signaling pathways involved in hepatic inflammation [33].”
InfluentialDing, M., Li, X., Wei, Y., Wang, J., Jiao, B., Li, C., Ma, W., Peng, Y., Shen, J., Yu, G., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117174
“35,36 Moreover, our in vitro experiments confirmed that all three drugs directly suppress TGF-β -induced fibrosis and cisplatin-induced senescence-associated fibrosis.”
Bhullar, J. K., & Bahekar, A. (2026) · The Egyptian Heart Journal · doi:10.1186/s43044-026-00767-y
张, 晓. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1672703
Anaspure, O. S., Sivaram, P., Guruprasad, P., Anaspure, A. S., Kadakia, R. J., & Anastasio, A. T. (2026) · The Journal of Foot & Ankle Surgery · doi:10.1053/j.jfas.2026.07.011 · Cited by 1
Metabolic and Digestive Functions of Glucagon-Like Peptide-1 in Pigs
Čulka, Ľ., Krepelková, Z., Bárdová, K., & Novotny, J. F. (2026) · Folia veterinaria · doi:10.2478/fv-2026-0018
“patients with type 2 diabetes, several beneficial actions beyond glycaemic control have been documented [32, 33, 34].”
Rebooting blood vessel repair: implications of the SEMA-VR CardioLink-15 trial
Verma, R., Verma, M., Park, B., Teoh, H., Quan, A., Connelly, K. A., & Hess, D. A. (2026) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001323
Teunis, C. J., Collins, T. J. C., Oostveen, R. F., Neele, A. E., de Winther, M. P. J., Nurmohamed, N. S., Heijmans, J., Winkelmeijer, M., Dzobo, K. E., Cooper, M. E., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag627
Ritter, A., Kreis, N., Louwen, F., & Yuan, J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag029
Webster, S. E., Terry, J., Tsuji, N. L., Heck, D., & Holodick, N. E. (2026) · ImmunoHorizons · doi:10.1093/immhor/vlag038
Semaglutide mechanisms of action: the missing pieces
Verma, S., Guzik, T. J., & Cosentino, F. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag602
Papastathopoulou, N. S., Neri, S., Assirelli, E., D’Amuri, A., Greco, S., Ciaffi, J., & Ursini, F. (2026) · Rheumatology Advances in Practice · doi:10.1093/rap/rkag105
Zarówna, K., Pura, W., Mazur, J., Marciniak, J., Kosowski, M., Matecka, D., Śliwiński, W., & Chołuj, D. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4791
From risk factor to therapeutic target: obesity therapy and cardiovascular outcomes
Arbel, R., & Dicker, D. (2026) · Heart · doi:10.1136/heartjnl-2026-327845
GIORGIO, C. M., Romanò, C., Arisi, M., Rossi, M., Venturini, M., Mezzana, S., Grigolato, L., Gallì, B., Nicoletti, M. M., Tomasi, C., et al. (2026) · Dermatology and Therapy · doi:10.1007/s13555-026-01916-6
Mikołajuk, A., Mallah, R., Kozdroń, D. J., Nieścioruk, M. W., Szczepańska, P., Kowalski, J., Dutkiewicz, D., & Yarbou, A. E. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5581
Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis
Tavaglione, F., & Loomba, R. S. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103023 · Cited by 1
“13 26 In preclinical models, GLP-1 receptor agonists suppressed key inflammatory signaling pathways, including NF-κ B, JNK, and the NLRP3 inflammasome, resulting in reduced expression and production of pro-inflammatory cytokines such as TNF, IL-1 β , and IL-6.”
Pavshintsev, V. V., Erbaeva, A. Z., Vatlin, A. A., & Mitkin, N. A. (2026) · Biomedicines · doi:10.3390/biomedicines14091987
“Semaglutide, a GLP-1RA widely used as an anti-diabetic medication, induces mitochondrial function in certain tissues [13–15], and its systemic anti-inflammatory action has been reported in many instances [28].”
Beniwal-Patel, P. M., Samaan, S., Abreu, M. T., Deepak, P., & Yarur, A. J. (2026) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izag151 · Cited by 2
Kayali, H., Adio, A. A., Parmar, T., Sumiyoshi, N., & Boakye, L. A. T. (2026) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-26-00153
Prospects for the use of new antidiabetic drugs in rheumatology
Nasonov, E. L., Shestakova, M. V., Kondratyeva, L. V., & Елисеев, М. С. (2026) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2026-315-334 · Cited by 1
Tsalouchos, A., & Dattolo, P. C. G. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176550
The adipose organ–capacitor model of preclinical and clinical obesity
Nisoli, E. (2026) · Trends Open · doi:10.1016/j.treopn.2026.07.013
Sepsis and infectious outcomes for GLP-1R agonists in CKD plus type 2 diabetes
Tseng, Y.-Y., Wang, H., Chen, J., Jiang, M., Lai, C., & Chuang, M. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag175
Inzucchi, S. E. (2026) · Diabetes Care · doi:10.2337/dci26-0047
Clinical Impact of Semaglutide in Patients with Heart Failure and Preserved Ejection Fraction
Hida, Y., Imamura, T., & Kinugawa, K. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124831
“…or sodium-glucose cotransporter 2 inhibitors [22–24]—which act primarily through neurohormonal or renal mechanisms—GLP-1RAs offer a different profile of pleiotropic effects including adiposity reduction, glycemic improvement, blood pressure lowering, and anti-inflammation action [25,26].”
Gómez-Maldonado, I., Rodríguez-Arana, A., Tamayo-Pinzón, A., Albornoz-Suárez, J. E., Lopez-Franco, M. J., Mejia-Manrique, J. A., Forero-Caycedo, J. J., Rojas-Rodríguez, L. C., Buitrago-Ricaurte, N., Gaviria-Carrillo, M., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167108
“Therefore, the reduction in adipogenic and lipogenic gene expression observed with GLP-1 treatment may indirectly counteract metabolic pathways implicated in OSA-related dyslipidemia [112].”
Appetite, Obesity, Metabolism, and Malignancy: Do Incretin-Mimetic Drugs Reduce Cancer Risk?
Renehan, A. G., & Pollak, M. (2026) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-26-0018 · Cited by 2
Metadata
- Authors
- Wong, C. K., & Drucker, D. J.
- Affiliations
- Lunenfeld-Tanenbaum Research Institute (CA)
- University of Toronto (CA)
- Corresponding author
- Drucker, Daniel J.
- Venue
- Journal of Clinical Investigation
- Published
- 2025-11-03
- Volume
- 135
- Issue
- 21
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC12578379
- OpenAlex
- W4415855223
- Semantic Scholar
- 4076facbe68bf6ad70262f15cb231a58eed3a21f
- Cited by
- 112
- References
- 92
- Citations by year
- 2026: 111 · 2025: 1
- FWCI
- 15.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Diabetes Canada
- Novo Nordisk (154321)
- Canadian Institutes of Health Research (15432_1, 19204)
- Banting and Best Diabetes Centre, University of Toronto (154321)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucagon-like peptide-1, GLP-1 receptor signaling, anti-inflammatory activity, inflammation, type 2 diabetes, obesity, cardiovascular disease, chronic kidney disease, metabolic liver disease, arthritis, substance use disorders, neurodegenerative diseases, weight loss
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Anti-Inflammatory Agents, Diabetes Mellitus, Type 2, Humans, Inflammation, Obesity, Signal Transduction, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.